首页> 外文期刊>Journal of Pathology: Journal of the Pathological Society of Great Britain and Ireland >The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant
【24h】

The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant

机译:胃类型,幽门腺变体的胰腺导管内微管乳头状肿瘤和导管内乳头状黏液性肿瘤的离散性和分子特征

获取原文
获取原文并翻译 | 示例
           

摘要

Intraductal tubulopapillary neoplasms (ITPNs) are composed of tubulopapillary glands with high-grade dysplasia in the pancreatic duct. Intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant (IPMN-PGs) are composed of tubular glands mimicking pyloric glands with low-grade dysplasia and were formerly called intraductal tubular adenomas. Because of their apparent common tubular morphology, IPMN-PGs and ITPNs could be associated. While the former might progress to the latter, this has not been fully assessed. In this study, we compared the molecular features of ITPNs and IPMN-PGs to determine their association using formalin-fixed, paraffin-embedded tissues of 14 ITPNs and 15 IPMN-PGs. Somatic mutations in PIK3CA, GNAS, KRAS, and BRAF were determined by Sanger sequencing. Expression of phosphorylated AKT was examined by immunohistochemistry. Somatic PIK3CA mutations were found in 3 of 14 ITPNs (21.4%) but in none of the IPMN-PGs (p = 0.0996). In contrast, GNAS mutations were found in none of the ITPNs but in 9 of 15 IPMN-PGs (60.0%; p < 0.001). KRAS mutations were detected in 1 of 14 ITPNs (7.1%) and 12 of 15 IPMN-PGs (80.0%; p < 0.001). BRAF mutation was found in one ITPN but in none of the IPMN-PGs. Phosphorylated AKT expression in ITPNs was significantly more evident than that in IPMN-PGs (p = 0.0401). These results indicate that ITPNs and IPMN-PGs are molecularly distinct, suggesting that IPMN-PG does not progress to ITPN. Furthermore, the molecular features of IPMN-PGs are confirmed to be identical to those of IPMNs reported elsewhere. These results validate the current World Health Organization system that classifies pancreatic intraductal neoplasms into IPMN and ITPN and confirm that IPMN-PG is not a benign counterpart of ITPN. The term 'intraductal tubular adenoma' should be eliminated and replaced with IPMN-PG.
机译:导管内的肾小管乳头状瘤(ITPN)由胰管中高度不典型增生的肾小管乳头状腺体组成。胃类型的导管内乳头状粘液性肿瘤,幽门腺变体(IPMN-PG)由模仿低度不典型增生的幽门腺的小管腺组成,以前称为小管内小管腺瘤。由于IPMN-PG和ITPN具有明显的共同的肾小管形态,因此它们可能是相关的。尽管前者可能会发展到后者,但尚未对其进行充分评估。在这项研究中,我们比较了14种ITPN和15种IPMN-PG的福尔马林固定,石蜡包埋的组织,比较了ITPNs和IPMN-PG的分子特征,以确定它们的缔合。通过Sanger测序确定PIK3CA,GNAS,KRAS和BRAF中的体细胞突变。通过免疫组织化学检查磷酸化的AKT的表达。在14个ITPN中有3个(21.4%)发现了体细胞PIK3CA突变,但在IPMN-PG中均未发现(p = 0.0996)。相反,在15个IPMN-PG中,没有一个在ITPNs中发现GNAS突变(60.0%; p <0.001)。在14个ITPN中有1个(7.1%)和15个IPMN-PG中有12个(80.0%; p <0.001)检测到KRAS突变。在一个ITPN中发现了BRAF突变,但在IPMN-PG中均未发现。 ITPNs中磷酸化的AKT表达明显高于IPMN-PGs(p = 0.0401)。这些结果表明,ITPNs和IPMN-PGs在分子上是不同的,这表明IPMN-PG不会发展为ITPN。此外,已确认IPMN-PG的分子特征与其他地方报道的IPMN相同。这些结果验证了当前的世界卫生组织系统,该系统将胰管内肿瘤分为IPMN和ITPN,并确认IPMN-PG不是ITPN的良性对应物。应删除术语“导管内管状腺瘤”,并以IPMN-PG代替。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号